1. X
  2. Toni Choueiri, MD
Log inSign up
Toni Choueiri, MD
28.1K posts
Image
user avatar
Toni Choueiri, MD
@DrChoueiri
Chief GU Cancers @DanaFarber II Prof Medicine @HarvardMed II ⚽ lover II @PanMass 🚲rider.
Boston, MA
dana-farber.org/find-a-doctor/…
Joined January 2016
347
Following
45.1K
Followers
1
Subscription
RepliesRepliesMediaMedia

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • Pinned
    user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Jan 19
    Dear Friends, Family, and Colleagues, I am honored and excited to share that I have registered for my 9th @PanMass as part of teammorecowbell.com. Each year, PMC gives all of us an opportunity to take action in the fight against cancer—a cause that defines my professional
    Image
    Image
    19K019K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Mar 28, 2020
    #COVID19 course in 1 slide @OncoAlert
    Image
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Mar 19, 2020
    In case you are wondering about IL-6 inhibitor Tociluzumab effect in #COVID19 serious infections: N=20. 19/20 discharged in 2 weeks. Improvement in lung lesions. Reduction in fever/C-reactive protein, increase O2 saturation among others. LINK to paper chinaxiv.org/abs/202003.000…
    Image
    Image
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Dec 29, 2022
    It is this time of the year again: TOP 10 GU Oncology clinical papers/trials in 2022: Some negative, some positive, but we learned from all! Feel free to add more & retweet & tag anyone involved This is not an exhaustive list! @OncoAlert @DanaFarber #OnwardFor2023
    Image
    189K0189K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Jan 1, 2025
    END OF YEAR TOP ALL CANCER TRIALS in 2024! JUST in on 1 JAN 2025: Paper 1: #neoadjuvant checkpoint inhibitor Phase 3 trial in melanoma! #NADINA trial shows ipi+nivo significantly improves EFS vs. adjuvant nivo alone (HR 0.32, p<0.0001). #ASCO24 plenary #Melanoma @ASCO
    Image
    Image
    111K0111K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Jan 12, 2021
    The paper that every cancer researcher saves, Cancer Statistics 2021 now published by @AmericanCancer. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…
    Image
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Oct 22, 2023
    #Goosebumps #EV302 #ESMO23 Took 3 decades but a new SOC in 1L bladder cancer !!!!!! ⁦@tompowles1⁩ EV+Pembro irrespective…..WOW! 🤩
    Image
    Image
    62K062K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Apr 17, 2024
    1/ The long-awaited OS results from #KEYNOTE-564 are out @NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…
    Image
    107K0107K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Feb 5, 2025
    1/ JUST IN: an 8 year #kidneycancer journey now published in @Nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author @BraunMDPhD @YaleCancer and #PatrickOtt #DerinKeskin
    Image
    171K0171K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Sep 11, 2022
    A waterfall plot or a tidal wave 🌊???? 🤩 😯 99% pathologic response with nivo/ipi in dMMR CRC and NO disease recurrences!! #ESMO22 ⁦@myESMO⁩ ⁦@MyriamChalabi⁩
    Image
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Dec 30, 2023
    Now, the TOP 10 Clinical Trials in 2023. Not an exhaustive list. Many practice-changing and practice-informing trials! Feel free to add! @OncoAlert @TargetedOnc @OncLive @gotoPER @FDAOncology @OncBrothers
    Image
    195K0195K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Nov 18, 2021
    JUST IN: @US_FDA approves pembrolizumab for adjuvant treatment of RCC at intermediate-high/high risk of recurrence following nephrectomy, or following nephrectomy + resection of metastases. 1st adjuvant immunotherapy in RCC! fda.gov/drugs/resource… @DanaFarber @OncoAlert
    Image
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    Dec 27, 2024
    IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:
    Image
    Image
    83K083K
  • user avatar
    Toni Choueiri, MD
    @DrChoueiri
    May 10, 2023
    1/ Results from #COSMIC-313 are out @NEJM: 1st triplet combo (cabo/nivo/ipi) in #mRCC vs. a modern control (nivo/ipi). Initially presented as Plenary #ESMO22 session chaired by @CharlesSwanton @AndresC27622123 #ESMO22 Thread 🧵==> nejm.org/doi/full/10.10…
    Image
    148K0148K
Advertisement
Advertisement